Literature DB >> 12630659

New anticonvulsants: a review of applications for the management of substance abuse disorders.

John R Gentry1, Caroline Hill, Robert Malcolm.   

Abstract

Substance abuse and related disorders are a major problem in the United States and elsewhere. In many cases, pharmacotherapy has been shown to be useful in the treatment of substance abuse and related disorders, both in detoxification and in the prevention of relapse. However, currently used medications are not ideal, due either to their effectiveness being less than desirable or their side effect profiles being greater than desirable, or both. Medications with increased effectiveness or decreased side effects are needed. This article reviews three anticonvulsant medications, gabapentin, oxcarbazepine, and tiagabine, for possible utility in the treatment of substance abuse and related disorders. The following aspects of each medication are discussed: metabolism and kinetics, dosage and administration, possible interactions, side effects, and applications to substance abuse treatment; the last subject includes discussion of management of withdrawal symptoms, treatment of dual diagnosis, management of substance abuse sleep disorders, direct suppression of substance abuse/relapse prevention, and abuse potential. Each medication appears to have potential advantages for these uses, and further study of these medications in treatment of substance abuse disorders is recommended.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12630659     DOI: 10.1023/a:1021921118070

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  8 in total

Review 1.  Comorbid Insomnia and Psychiatric Disorders: An Update.

Authors:  Khurshid A Khurshid
Journal:  Innov Clin Neurosci       Date:  2018-04-01

2.  Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat.

Authors:  Serena Stopponi; Lorenzo Somaini; Andrea Cippitelli; Giordano de Guglielmo; Marsida Kallupi; Nazzareno Cannella; Gilberto Gerra; Maurizio Massi; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-02       Impact factor: 4.530

3.  Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.

Authors:  Nichole C Sanders; Michael J Mancino; W Brooks Gentry; J Benjamin Guise; Warren K Bickel; Jeff Thostenson; Alison H Oliveto
Journal:  Exp Clin Psychopharmacol       Date:  2013-07-15       Impact factor: 3.157

4.  Tiagabine does not attenuate alcohol-induced activation of the human reward system.

Authors:  Christoph Fehr; Nina Hohmann; Gerhard Gründer; Thomas F Dielentheis; Hans-Georg Buchholz; Natalie Chechko; Igor Yakushev; Christian Landvogt; Peter Bartenstein; Reinhard Urban; Mathias Schreckenberger
Journal:  Psychopharmacology (Berl)       Date:  2007-01-30       Impact factor: 4.530

5.  Cellular and behavioral interactions of gabapentin with alcohol dependence.

Authors:  Marisa Roberto; Nicholas W Gilpin; Laura E O'Dell; Maureen T Cruz; Andrew C Morse; George R Siggins; George F Koob
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

Review 6.  Efficacy and tolerability of pharmacotherapies for borderline personality disorder.

Authors:  Silvio Bellino; Erika Paradiso; Filippo Bogetto
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016.

Authors:  Nathan J Pauly; Chris Delcher; Svetla Slavova; Eric Lindahl; Jeff Talbert; Patricia R Freeman
Journal:  J Manag Care Spec Pharm       Date:  2020-03

Review 8.  Chromanone-A Prerogative Therapeutic Scaffold: An Overview.

Authors:  Sonia Kamboj; Randhir Singh
Journal:  Arab J Sci Eng       Date:  2021-06-30       Impact factor: 2.807

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.